Mulder C J, Tytgat G N
Ziekenhuis Rijnstate, Arnhem, The Netherlands.
Aliment Pharmacol Ther. 1993 Apr;7(2):125-30. doi: 10.1111/j.1365-2036.1993.tb00080.x.
It would be ideal to treat inflammatory bowel disease with topical corticosteroids that are either not absorbed through the mucosa, or have a substantial first-pass hepatic metabolism. The topical use of hydrocortisone, prednisolone-21-phosphate or betamethasone is often associated with systemic side-effects. Newer corticosteroid preparations (prednisolone metasulphobenzoate, tixocortol pivalate, fluticasone propionate, beclomethasone dipropionate and budesonide) are usually associated with minimal systemic corticosteroid activity. This article reviews the clinical activity and safety of these newer preparations.
